Article Text

Download PDFPDF
Treatment of high-risk bleeding with susoctocog alfa in a patient with acquired haemophilia A and a nosocomial severe acute respiratory syndrome coronavirus 2 infection
  1. Carla Fernández-Oliveira1,
  2. Sandra Rotea-Salvo1,
  3. Marta Fernández-Docampo2,
  4. Sara González-Piñeiro1,
  5. Isabel Martín-Herranz1
  1. 1 Pharmacy, Complexo Hospitalario Universitario A Coruna, A Coruna, Spain
  2. 2 Hematology, Complexo Hospitalario Universitario A Coruna, A Coruna, Spain
  1. Correspondence to Sandra Rotea-Salvo, Pharmacy, Complexo Hospitalario Universitario A Coruna, A Coruna 15006, Spain; sandra.rotea.salvo{at}


We report the case of a man in his early 70s with idiopathic acquired haemophilia A and persistent high-titre type II inhibitors on immunosuppressive treatment to eradicate the inhibitor. As complications, he had a nosocomial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which caused severe pneumonia and an explosive inflammatory reaction that required tocilizumab and remdesivir treatment, and a high-risk retroperitoneal haematoma. Recombinant porcine factor VIII, susoctocog alfa, was requested from the Pharmacy Service in view of the extreme risk of thromboembolism resulting from the concomitant inflammatory storm caused by SARS-CoV-2. Improvement in the SARS-CoV-2 infection made it possible to complete the immunosuppressive treatment with rituximab. The patient was discharged with mycophenolate mofetil as immunosuppressive treatment after 89 days in hospital and 22 days of treatment with susoctocog alfa. His SARS-CoV-2 infection resolved and the haematoma evolved favourably.

  • COVID-19
  • clinical laboratory techniques
  • drug-related side effects and adverse reactions
  • drug monitoring
  • hematology
  • pharmaceutical preparations

Data availability statement

All data relevant to the study are included in the article.

This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.